Jasper Therapeutics Inc (JSPR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $15.18M
Last updated: Nov 17, 2026 at 4:10 PM ET
Jasper Therapeutics Inc (JSPR) Statistics
Jasper Therapeutics (JSPR) has a market cap of $15.18M. It kept -1968.63% of revenue as net income over the last 12 months. It holds $135.35M more cash than debt, 891.35% of its market cap.
Total Valuation
| Market Cap | $15.18M |
|---|---|
| Latest price (Nov 17, 2026) | $10.34 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 16, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 1.4x.
| P/S Ratio | 1.4x |
|---|---|
| Forward P/S | 2.5x |
Price Statistics
The stock is down 79.48% over 52 weeks and trades 36.87% below its 50-day average.
| Beta (1Y) | 1.82 |
|---|---|
| 52-Week Change | -79.48% |
| 1-Month Change | -27.80% |
| 3-Month Change | -53.84% |
| 6-Month Change | -57.88% |
| 5-Year Change | -99.43% |
| Total Return (1Y) | -79.48% |
| Total Return (3Y CAGR) | -62.01% |
| Total Return (5Y CAGR) | -66.57% |
| Return vs SPY (1Y) | -92.72% |
| Max Drawdown (1Y) | -83.37% |
| Max Drawdown (3Y) | -98.86% |
| Sharpe Ratio (1Y) | -1.54 |
| Correlation with SPY (1Y) | 0.23 |
| 50-Day Average | $16.38 |
| 200-Day Average | $23.63 |
| 52-Week Range | $9.45 to $62.10 |
| RSI (14 Days) | 30.4 |
| Average Volume (20 Days) | 302.31K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 10.59x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 10.59x |
|---|---|
| Quick Ratio | 10.59x |
| Debt / Equity | 0.00x |
Returns and Efficiency
| Return on Assets (ROA) | -106.83% |
|---|---|
| ROA (5Y Average) | -95.93% |
| Asset Turnover | 0.08x |
| Receivables Turnover | 2.00x |
Scores
JSPR has an Altman Z-Score of -6.52, in the distress zone below 1.81, and a Piotroski F-Score of 0 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -6.52 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 0 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $8.00M over the last 12 months is up 581.43% from the 12 months before.
| Revenue | $8.00M |
|---|---|
| Revenue Growth (YoY) | +581.43% |
| Gross Profit | -$283.00K |
| Operating Income | -$180.17M |
| Pretax Income | -$157.49M |
| Net Income | -$157.49M |
| Reported EPS (TTM) | -$2.22 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $135.35M |
|---|---|
| Total Debt | $0 |
| Net Cash | $135.35M |
| Net Cash Per Share | $125.88 |
| Working Capital | $133.36M |
| Shareholder Equity | -$140.25M |
| Total Assets | $147.42M |
| Total Liabilities | $20.89M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$48.83M |
|---|---|
| FCF Per Share | -$43.99 |
| Depreciation and Amortization | $349.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -2252.14%.
| Gross Margin | -3.54% |
|---|---|
| Operating Margin | -2252.14% |
| Pretax Margin | -1968.63% |
| Net Margin | -1968.63% |
Growth
| Book Value Per Share Growth (2Y CAGR) | -80.48% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -80.48% |
Dividends and Yields
JSPR does not pay a dividend.
| Buyback Yield | 3.06% |
|---|---|
| Shareholder Yield | 3.06% |
Stock Splits
The last split was a 1-for-30 reverse split on Nov 6, 2026.
| Last Split Date | Nov 6, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:30 |
Peer Position
Against 5 similar companies, JSPR has the lowest P/S.
P/S RatioPeer median 6.6x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -51.00%
| P/S Ratio | 1.4x vs 6.6x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +581.43% vs -51.00% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About JSPR
What is JSPR's market cap?
Jasper Therapeutics has a market cap of $15.18M.
How many shares of JSPR are outstanding?
Jasper Therapeutics has 1.08M shares outstanding. The count is up 84.10% from a year earlier.
Does JSPR pay a dividend?
No. Jasper Therapeutics does not pay a dividend.
How much debt does JSPR have?
Jasper Therapeutics has $0 of total debt and $135.35M of cash and equivalents, a net cash position of $135.35M.
JSPR pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors